• 1. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 2. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 3. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

Recent Advances in the Study of (2-bromo-3,5-difluoro-4-pyridyl)methanol (CAS: 2306265-44-9) and Its Applications in Chemical Biology and Pharmaceutical Research

In recent years, the compound (2-bromo-3,5-difluoro-4-pyridyl)methanol (CAS: 2306265-44-9) has garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its bromo and difluoro substituents on the pyridine ring, has demonstrated potential as a versatile building block for the synthesis of novel bioactive molecules. Its unique structural features make it an attractive candidate for drug discovery, particularly in the development of enzyme inhibitors and receptor modulators.

A recent study published in the Journal of Medicinal Chemistry explored the utility of (2-bromo-3,5-difluoro-4-pyridyl)methanol as a precursor for the synthesis of kinase inhibitors. The researchers employed a multi-step synthetic route to derivatize the compound, yielding a series of analogs with varying degrees of potency against specific kinase targets. Notably, one of the analogs exhibited nanomolar inhibitory activity against a clinically relevant kinase, highlighting the potential of this scaffold in oncology drug development.

Further investigations into the mechanistic aspects of (2-bromo-3,5-difluoro-4-pyridyl)methanol derivatives have revealed their ability to form stable interactions with key amino acid residues in enzyme active sites. X-ray crystallography studies have provided structural insights into these interactions, demonstrating how the bromo and difluoro substituents contribute to binding affinity and selectivity. These findings have important implications for rational drug design, as they offer a blueprint for optimizing the pharmacological properties of related compounds.

In addition to its applications in kinase inhibition, (2-bromo-3,5-difluoro-4-pyridyl)methanol has also been investigated as a starting material for the synthesis of fluorinated pyridine-based ligands. A recent report in ACS Chemical Biology described the use of this compound in the development of positron emission tomography (PET) tracers. By incorporating fluorine-18 isotopes, researchers were able to create radiolabeled probes for imaging studies, opening new avenues for diagnostic applications in neurology and oncology.

The safety profile and pharmacokinetic properties of (2-bromo-3,5-difluoro-4-pyridyl)methanol derivatives have also been a subject of recent research. In vitro and in vivo studies have shown that these compounds generally exhibit favorable metabolic stability and low toxicity, making them promising candidates for further preclinical development. However, challenges remain in optimizing their bioavailability and tissue distribution, which are areas of active investigation.

Looking ahead, the versatility of (2-bromo-3,5-difluoro-4-pyridyl)methanol as a synthetic intermediate suggests that it will continue to play an important role in medicinal chemistry. Ongoing research is exploring its potential in other therapeutic areas, including infectious diseases and inflammation. As synthetic methodologies advance and our understanding of structure-activity relationships deepens, this compound is likely to contribute to the development of new classes of therapeutic agents with improved efficacy and safety profiles.

• 325461-60-7(2,6-Dibromo-3,5-difluoroisonicotinic acid)
• 885168-20-7(2-Bromo-5-fluoro-4-methylpyridine)
• 1211530-89-0(2-Bromo-3-fluoroisonicotinic acid)
• 1227502-29-5((2-Bromo-5-fluoropyridin-4-yl)methanol)
• 884494-37-5(2-Bromo-3-fluoro-4-picoline)
• 885588-12-5(2-bromo-5-fluoropyridine-4-carboxylic acid)
• 1114523-54-4(1-(2-Bromo-5-fluoropyridin-4-yl)ethan-1-ol)
• 2167544-51-4((2,5-Dibromo-3-fluoropyridin-4-yl)methanol)
• 1227502-23-9((6-Bromo-5-fluoropyridin-3-yl)methanol)
• 1227601-75-3(2-Bromo-3-fluoro-4-(hydroxymethyl)pyridine)